Clinical Trials Browser

Phase 3 × INDUSTRY × Oxaliplatin × Clear all

NCT07412613 2026-04-22

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Phase 3 Recruiting

GastrointestinalOther solid neoplasm

Resectable Colon Cancer

NCT04083235 2026-04-20

NAPOLI 3

Phase 3 Completed

770 enrolled 13 charts 2 FDA

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT06997497 2026-04-20

KANDLELIT-012

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 2 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05152147 2026-04-17

HERIZON-GEA-01

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT05239741 2026-04-17

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07409272 2026-04-16

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Phase 3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06662786 2026-04-13

OrigAMI-2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07522151 2026-04-13

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT07265674 2026-04-09

Beacon-BTC

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06508658 2026-04-08

EPCORE DLBCL-4

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05253651 2026-04-07

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07228832 2026-04-06

HARMONi-GI3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06901531 2026-04-03

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT05568095 2026-04-02

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07409428 2026-04-01

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04384484 2026-03-24

LOTIS 5

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

Phase 3 Completed

120 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05171647 2026-03-06

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Phase 3 Recruiting

Gastrointestinal

Colorectal Adenocarcinoma

NCT03675737 2026-02-27

KEYNOTE-859

Phase 3 Completed

1,579 enrolled 31 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 2 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05700448 2026-02-05

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Phase 3 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Not yet recruiting

Adenocarcinoma

NCT04854668 2026-01-30

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Phase 3 Not yet recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT04949256 2025-12-15

MK-7902-014

Phase 3 Active not recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT06625320 2025-12-12

RASolute 302

Phase 3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03615326 2025-12-11

MK-3475-811

Phase 3 Completed

738 enrolled 22 charts 6 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT07238283 2025-12-09

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

Phase 3 Recruiting

Gastrointestinal

First-line Treatment of Metastatic Pancreatic Cancer

NCT06929624 2025-11-18

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 4 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT00680901 2025-08-07

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Phase 3 Completed

545 enrolled 24 charts

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 2 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

649 enrolled 22 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07025239 2025-06-17

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03478488 2025-05-29

KN035-BTC

Phase 3 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04210115 2024-11-15

KEYNOTE 975

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma